Linezolid is the antibiotic of choice for MRSA cellulitis in patients allergic to doxycycline, clindamycin, and sulfa drugs.
For outpatient oral therapy, linezolid 600 mg twice daily is your best option, as it provides reliable MRSA coverage and has proven in-vivo effectiveness for skin and soft tissue infections. 1, 2 If the patient requires intravenous therapy due to systemic signs of infection or severity, vancomycin remains the standard choice. 3, 2
Clinical Decision Framework
Severity Assessment First
- Mild cellulitis without systemic signs: Outpatient oral therapy is appropriate 3
- Moderate to severe with systemic signs (fever, tachycardia, hypotension): Hospitalization with IV vancomycin is recommended 3
Why Linezolid for This Patient
Given your patient's multiple allergies (doxycycline, clindamycin, sulfa drugs), you've eliminated the three most common oral MRSA options. Linezolid is the only remaining oral antibiotic with both proven MRSA activity and documented clinical efficacy for skin and soft tissue infections. 1, 4
Key advantages:
- Excellent oral bioavailability (100%)
- High clinical cure rates in MRSA skin infections 4
- Penetrates soft tissues effectively
- Can also treat CNS infections if needed 1
Alternative IV Options
If oral therapy is insufficient or the patient has systemic signs:
Vancomycin is the first-line IV choice for hospitalized patients with MRSA cellulitis due to its efficacy, safety profile, and low cost 2. The IDSA guidelines specifically recommend vancomycin for severe nonpurulent cellulitis requiring MRSA coverage 3.
Daptomycin is the most potent anti-MRSA agent and particularly useful for:
- Persistent bacteremia
- Treatment failures with vancomycin
- When rapid, effective therapy is critical 1
Tigecycline is another IV option with MRSA coverage, though published data for skin infections are more limited 2.
Important Caveats
Duration
Treat for 5 days minimum, extending therapy if infection hasn't improved 3. This is shorter than traditional 10-14 day courses.
Linezolid-Specific Warnings
- Monitor for thrombocytopenia with prolonged use (>2 weeks)
- Risk of serotonin syndrome with certain medications
- Higher cost than other options (though this is secondary to efficacy in your allergic patient) 4
Don't Forget Adjunctive Measures
- Elevate the affected extremity 3
- Examine interdigital toe spaces for tinea pedis—treating this reduces recurrence risk 3
- Address underlying edema or skin conditions 3
Common Pitfall
Do not assume MRSA coverage is always necessary. The IDSA guidelines only recommend MRSA coverage for cellulitis with specific risk factors: penetrating trauma, purulent drainage, injection drug use, known MRSA colonization, or systemic inflammatory response syndrome 3. However, since you're asking specifically about MRSA coverage, I'm assuming these risk factors are present in your patient.
When to Hospitalize
Admit if the patient has:
- Systemic inflammatory response syndrome (SIRS)
- Hemodynamic instability
- Altered mental status
- Concern for deeper/necrotizing infection
- Severe immunocompromise 3